APA (7th ed.) Citation

RA, L., SJ, M., LJ, H., BL, S., K, L., S, G., . . . RM, S. (2021). Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: The Alliance CALGB 10603/RATIFY trial. Leukemia, 35(9), 2539. https://doi.org/10.1038/s41375-021-01179-4

Chicago Style (17th ed.) Citation

RA, Larson, et al. "Midostaurin Reduces Relapse in FLT3-mutant Acute Myeloid Leukemia: The Alliance CALGB 10603/RATIFY Trial." Leukemia 35, no. 9 (2021): 2539. https://doi.org/10.1038/s41375-021-01179-4.

MLA (9th ed.) Citation

RA, Larson, et al. "Midostaurin Reduces Relapse in FLT3-mutant Acute Myeloid Leukemia: The Alliance CALGB 10603/RATIFY Trial." Leukemia, vol. 35, no. 9, 2021, p. 2539, https://doi.org/10.1038/s41375-021-01179-4.